newsfilter
← Latest News
Business Wire·

Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026

Definium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders,